Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy

DV. Rizk, N. Maillard, BA. Julian, B. Knoppova, TJ. Green, J. Novak, RJ. Wyatt,

. 2019 ; 10 (-) : 504. [pub] 20190319

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025906

Grantová podpora
R01 DK078244 NIDDK NIH HHS - United States
R01 DK082753 NIDDK NIH HHS - United States
R56 DK078244 NIDDK NIH HHS - United States

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and a common cause of end-stage renal disease. Evaluation of a kidney biopsy is necessary for diagnosis, with routine immunofluorescence microscopy revealing dominant or co-dominant IgA immunodeposits usually with complement C3 and sometimes IgG and/or IgM. IgA nephropathy reduces life expectancy by more than 10 years and leads to kidney failure in 20-40% of patients within 20 years of diagnosis. There is accumulating clinical, genetic, and biochemical evidence that complement plays an important role in the pathogenesis of IgA nephropathy. The presence of C3 differentiates the diagnosis of IgA nephropathy from the subclinical deposition of glomerular IgA. Markers for the activation of the alternative and mannan-binding lectin (MBL) pathways in renal-biopsy specimens are associated with disease activity and portend a worse renal outcome. Complement proteins in the circulation have also been evaluated in IgA nephropathy and found to be of prognostic value. Recently, genetic studies have identified IgA nephropathy-associated loci. Within these loci are genes encoding products involved in complement regulation and interaction with immune complexes. Put together, these data identify the complement cascade as a rational treatment target for this chronic kidney disease. Recent case reports on the successful use of humanized anti-C5 monoclonal antibody eculizumab are consistent with this hypothesis, but a better understanding of the role of complement in IgA nephropathy is needed to guide future therapeutic interventions.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025906
003      
CZ-PrNML
005      
20201222160438.0
007      
ta
008      
201125s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fimmu.2019.00504 $2 doi
035    __
$a (PubMed)30941137
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Rizk, Dana V $u Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
245    14
$a The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy / $c DV. Rizk, N. Maillard, BA. Julian, B. Knoppova, TJ. Green, J. Novak, RJ. Wyatt,
520    9_
$a IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and a common cause of end-stage renal disease. Evaluation of a kidney biopsy is necessary for diagnosis, with routine immunofluorescence microscopy revealing dominant or co-dominant IgA immunodeposits usually with complement C3 and sometimes IgG and/or IgM. IgA nephropathy reduces life expectancy by more than 10 years and leads to kidney failure in 20-40% of patients within 20 years of diagnosis. There is accumulating clinical, genetic, and biochemical evidence that complement plays an important role in the pathogenesis of IgA nephropathy. The presence of C3 differentiates the diagnosis of IgA nephropathy from the subclinical deposition of glomerular IgA. Markers for the activation of the alternative and mannan-binding lectin (MBL) pathways in renal-biopsy specimens are associated with disease activity and portend a worse renal outcome. Complement proteins in the circulation have also been evaluated in IgA nephropathy and found to be of prognostic value. Recently, genetic studies have identified IgA nephropathy-associated loci. Within these loci are genes encoding products involved in complement regulation and interaction with immune complexes. Put together, these data identify the complement cascade as a rational treatment target for this chronic kidney disease. Recent case reports on the successful use of humanized anti-C5 monoclonal antibody eculizumab are consistent with this hypothesis, but a better understanding of the role of complement in IgA nephropathy is needed to guide future therapeutic interventions.
650    _2
$a zvířata $7 D000818
650    _2
$a komplement C3 $x imunologie $7 D003176
650    _2
$a komplement C5 $x imunologie $7 D003182
650    _2
$a glomerulonefritida $x imunologie $7 D005921
650    _2
$a IgA nefropatie $x imunologie $7 D005922
650    _2
$a lidé $7 D006801
650    _2
$a imunoglobulin A $x imunologie $7 D007070
650    _2
$a ledviny $x imunologie $7 D007668
650    _2
$a chronická renální insuficience $x imunologie $7 D051436
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Maillard, Nicolas $u Department of Nephrology, Dialysis, Transplantation, CHU de Saint-Etienne, GIMAP, EA3064, Université Jean Monnet, COMUE Université de Lyon, Rhône-Alpes, France.
700    1_
$a Julian, Bruce A $u Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
700    1_
$a Knoppova, Barbora $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States. Department of Immunology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czechia.
700    1_
$a Green, Todd J $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States.
700    1_
$a Novak, Jan $u Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, United States.
700    1_
$a Wyatt, Robert J $u Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN, United States.
773    0_
$w MED00181405 $t Frontiers in immunology $x 1664-3224 $g Roč. 10, č. - (2019), s. 504
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30941137 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222160433 $b ABA008
999    __
$a ok $b bmc $g 1600051 $s 1116592
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 10 $c - $d 504 $e 20190319 $i 1664-3224 $m Frontiers in immunology $n Front Immunol $x MED00181405
GRA    __
$a R01 DK078244 $p NIDDK NIH HHS $2 United States
GRA    __
$a R01 DK082753 $p NIDDK NIH HHS $2 United States
GRA    __
$a R56 DK078244 $p NIDDK NIH HHS $2 United States
LZP    __
$a Pubmed-20201125
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace